Home  »  Markets   »  Timber Pharmaceuticals Inc. (AMEX:TMBR): A Fundame...

Timber Pharmaceuticals Inc. (AMEX:TMBR): A Fundamentally Weighted Stock for Long-Term Investors

Timber Pharmaceuticals Inc. (AMEX:TMBR) shares traded higher over the last trading session, gaining 6.61% on 05/27/21. The shares fell to a low of $1.26 before closing at $1.29. Intraday shares traded counted 1.37 million, which was 78.23% higher than its 30-day average trading volume of 6.29M. TMBR’s previous close was $1.21 while the outstanding shares total 37.13M. The firm has a beta of 0.33. The stock’s Relative Strength Index (RSI) is 47.00, with weekly volatility at 8.21% and ATR at 0.14. The TMBR stock’s 52-week price range has touched low of $0.67 and a $3.65 high.

Investors have identified the Biotechnology company Timber Pharmaceuticals Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $47.90 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.

Timber Pharmaceuticals Inc. (TMBR) Fundamentals that are to be considered.

When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 8.79 million total, with 1.33 million as their total liabilities.

Potential earnings growth for Timber Pharmaceuticals Inc. (TMBR)

What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 41000.0 trying to sell their products during the last quarter, with the result yielding a gross income of 1.92 million. This allows shareholders to hold on to 37.13M with the recently reported earning now reading -0.05 cents per share. This is a figure that compared to analyst’s prediction for their 08/24/2021.

Is the stock of TMBR attractive?

In related news, Chief Medical Officer, Mendelsohn Alan bought 1,988 shares of the company’s stock in a transaction that recorded on Mar 03. The purchase was performed at an average price of 2.17, for a total value of 4,314. As the purchase deal closes, the 10% Owner, TardiMed Sciences LLC now sold 100,694 shares of the company’s stock, valued at 103,695. Also, 10% Owner, TardiMed Sciences LLC sold 87,060 shares of the company’s stock in a deal that was recorded on Sep 15. The shares were cost at an average price of 1.03 per share, with a total market value of 89,550. Following this completion of disposal, the 10% Owner, TardiMed Sciences LLC now holds 455 shares of the company’s stock, valued at 469. In the last 6 months, insiders have changed their ownership in shares of company stock by 15.33%.

Leave a Comment

Your email address will not be published. Required fields are marked *